key: cord-0828925-bmxb1p68 authors: Argoty-Pantoja, Anna D.; Robles-Rivera, Karina; Rivera-Paredez, Berenice; Salmerón, Jorge; DrSc, title: COVID-19 fatality in Mexico’s indigenous populations date: 2021-02-11 journal: Public Health DOI: 10.1016/j.puhe.2021.01.023 sha: 5bbffc48dec3d268d655cebc17199d3abd7179e2 doc_id: 828925 cord_uid: bmxb1p68 Objective Explore the factors that could explain the differences of fatality rates among indigenous groups with COVID-19 diagnosis compared to the rest of the population in Mexico. Study design We analyzed the public data of COVID-19 surveillance, of the Mexican Ministry of Health, to estimate COVID-19 fatality rates by ethnicity. Methods  We explored associated factors using Cox proportional hazards models stratified by outpatient and hospital management at diagnosis; analysis was conducted in three scenarios: national level, states with 89% of indigenous population, and South Pacific region. Results 412,017 COVID-19 cases were included, with 1.1% of indigenous population. Crude fatality rate per 1,000 person-weeks was 64.8% higher among indigenous than in non-indigenous (29.97 vs. 18.18, respectively), and it increased more than twice within outpatients (5.99 vs. 2.64). Cox analysis revealed that indigenous with outpatient management had higher fatality rate compared to non-indigenous outpatients; at national level (HR 1.63 95% CI 1.34-1.98), within the subgroup of 13 states (HR 1.66 95% CI 1.33-2.07), and South Pacific region (HR 2.35 95% CI 1.49-3.69). Factors associated with higher fatality rates among non-indigenous and indigenous outpatients were age, sex and comorbidities. Conclusions COVID-19 fatality is higher among indigenous populations, particularly within cases managed as outpatients. The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic has more serious repercussions in vulnerable groups: older people with comorbidities, homeless people, pregnant women and ethnic minority groups [1] [2] [3] . There are more than 476 million indigenous people in the world, which represent around 6% of the worldwide population 4,5 , in Mexico it is 10% of the total population 6, 7 . Indigenous populations are frequently affected by various crises due to the economic and social conditions they live in. Their communities are usually isolated or poorly communicated, with poor access to health services. In many cases, such health services have little capacity and limited coverage, which may delays seeking medical attention, complicating early management, and therefore, leading to greater risks of complications and mortality. Health disparities have been documented among ethnic minority groups who have a higher prevalence of metabolic disorders, such as diabetes 8 . The living conditions of indigenous populations in Mexico could place them into a higher impact of SARS-CoV-2 epidemic. The number of deaths can be used as a key indicator of the trajectory of COVID-19 in our country [9] [10] [11] . Various studies have identified factors associated with lower We performed a longitudinal analysis using the public data of the COVID-19 information derived from the Epidemiological Surveillance System of Viral Respiratory Diseases of suspected cases identified by the Healthcare System in Mexico 16 . The study population included those cases with a positive diagnosis for SARS-CoV-2 certified by the Institute for Diagnosis and Epidemiological Reference (InDRE); from February 27, 2020, where the first case in the country was officially reported, until July 30, 2020 (n= 424,637). A suspected case was defined as a "person of any age who had at least two of the following signs and symptoms in the last 7 days: cough, fever or headache accompanied by either dyspnea, arthralgias, myalgias, sore throat, rhinorrhea, conjunctivitis or chest pain", and the confirmed case, was the suspected case with a diagnosis confirmed by the InDRE 17 . Fatality rate was defined as the ratio of the number of deaths, occurred within the cohort study of confirmed COVID-19 cases, divided by the person-time at risk. of the patient's condition at the time of seeking care. This variable was defined according to the type of management at diagnosis: a) outpatient management (OM); b) hospital management (HM); c) management in intensive care unit (ICU) and/or with intubation and assisted ventilation. Indigenous population was defined as all individual who declared to speak an indigenous language. We conducted a descriptive analysis of the indigenous and non-indigenous population according to their survival condition. The person-time of the fatality rate was expressed in person-weeks according to the date from the symptom onset until death. Statistical differences between the nonsurvivor indigenous people vs. non-survivor non-indigenous people were tested using the immediate two-sample proportion test for categorical variables and the non-parametric Mann Whitney U test for numerical variables. In order to investigate risk factors of COVID-19 fatality, the Hazard Ratio (HR) and 95% Confidence Interval (CI) were calculated using the multivariable Cox proportional hazards regression models stratified by management at diagnosis. For variables that did not meet the proportional risk assumption, an interaction with time was performed 18, 19 . From this multivariable model, we explored the statistical significance of three-way interaction terms (indigenous*sex*time, indigenous*age groups*time and indigenous*comorbid conditions*time). In order to improve comparability among the populations groups, associations of interest were people is concentrated (34% -Oaxaca, Chiapas, and Guerrero). We excluded 12,610 cases without indigenous language information. There were no statistically significant differences in age (60.6 vs. 61.7, respectively), sex (men 66.1% vs. 64.9%) and comorbidities conditions such as diabetes (37.7% and 38%, respectively), hypertension (42.5% vs. 43.8%), or chronic obstructive pulmonary disease (4.6% vs. 4.8%) between excluded vs. included individuals. All analyses were performed using Stata 14.1 and Graphpad Prism 8.2. All p-values were two-tailed, and a p-value <0.05 was considered statistically significant. The average age of non-survivors of the non-indigenous population with COVID-19 was 61.7 years old (SD 14.2) and more than half were in the 35-64 age range, compared to 63.3 years of age (SD 13.4), and almost half of them were 65 years or older, in the indigenous population. In both groups, the majority were men. Most comorbidities were more frequent in the non-survivors in both non-indigenous and indigenous population: hypertension (43.9% vs. 39.1%, respectively), diabetes (38.1% vs. 36.5%), obesity (24.7% vs. 25.6%, respectively), COPD (4.8% vs. 7.6%), immunosuppression (2.7% vs. 2.6%), cardiovascular disease (5.3% vs. 4.6%), chronic kidney disease (6.9% vs. 5.5%), and smoking (8.3% vs. 7.1%), except for obesity (24.7% vs. 25.6%, respectively), and asthma (with higher prevalence in indigenous non-survivors) ( Table 1) . Considering all comorbidities, 64.4% of the indigenous people who died had one metabolic comorbidity at least, compared to 66.6% of the non-indigenous people who died, the most prevalent ones in both groups were: diabetes + hypertension, hypertension and diabetes. (Table J o u r n a l P r e -p r o o f 1). Regarding the initial medical management, the majority of survivors received OM, 80.5% of non-indigenous vs. 69.5% of indigenous people. A lower percentage of non-indigenous patients required hospitalization compared to indigenous (17.9% and 27.7%, respectively), as well as intensive care unit (ICU) and/or intubation (1.6% vs. 2.8%, respectively). Among non-survivors, the majority were hospitalized 69.2% of non-indigenous vs. 63.7% of indigenous people, followed by the ICU and/or intubation (19.6% of vs. 23%, respectively), and a lower percentage received OM (11.2% vs. 13.3%, respectively). The time from the symptom onset to seeking medical attention, as well as death was similar in indigenous and non-indigenous people. Finally, non-survivor indigenous people had an average time of 6.5 days (SD 7.2) from the beginning of hospitalization to death, compared to 7.7 days (SD 7.5) in non-indigenous people (Table 1) . When stratifying the analysis by type of management at diagnosis, we observed that the indigenous population had a higher crude fatality rate in both outpatients and hospitalized patients, compared to non-indigenous people. Furthermore, we observed a significant difference in outpatients, where the indigenous population had a crude fatality rate more than twice the rate among non-indigenous patients (6.0 vs. 2.6, respectively). These results were similar in the subgroup of the 13 states containing 89% of the total indigenous population (2.4 vs. 6.1, J o u r n a l P r e -p r o o f respectively) and in the South Pacific region (2.6 vs. 7.6, respectively). In addition, we observed differences in the time from symptom onset to seeking care (days) among non-indigenous outpatients and indigenous outpatients for the different regions, at the national level and in the 13 states we observed an average time of 4.2 days in non-indigenous vs. 3.9 in indigenous (p <0.01); however, in the South Pacific region, we observed that indigenous have a longer time seeking care compared to non-indigenous (4.5 vs. 4.2, p <0.001, respectively). Within the outpatient group, the men were the most affected ones, where indigenous people had a crude fatality rate of 132% more than non-indigenous people; when assessing age, indigenous people in the 35-64 age range had a crude fatality rate 119% higher than non-indigenous people of the same age group (Table 2) . Results from the Cox proportional hazards analysis showed that sex, age, and the presence of comorbidities (COPD, hypertension, obesity, diabetes, and chronic kidney disease) are associated with a higher COVID-19 fatality rate, both in outpatients and in hospitalized patients. Ethnicity was associated with a higher COVID-19 fatality rate in individuals with outpatient management, but not in individuals with hospital management, regardless of age, sex, and comorbidities. In outpatients, we found that being indigenous increases COVID- 19 In our data, after adjusting by sex, age and metabolic comorbidities, the fatality rate is particularly higher among indigenous outpatients than in non-indigenous outpatients, while the fatality rates in hospitalized patients (indigenous and non-indigenous) are the same, at the three regions in Mexico (national, 13 states and South Pacific region). Similar results were found in Georgia, USA, where fatality rate during hospitalization was similar between African-Americans and other ethnic groups 23 . When analyzing the differences in the prevalence of various comorbidities, it was found that nonsurvivor indigenous people had a higher frequency of comorbidities, being most affected by chronic and metabolic diseases, corresponding to the elevated prevalence of metabolic syndrome, central obesity, and hypertension in indigenous communities in Mexico 24 . Historically, the indigenous population has shown poor health indicators in high rates of morbidity, disability, and early mortality, which are related to their own social, environmental, geographic, and cultural conditions. Access barriers are well-known factors that affects health results of these communities 9, 10, 25 . Unfortunately, the dataset we used for this analysis is only a J o u r n a l P r e -p r o o f public administrative information, we acknowledge the dataset lacks variables that measure access to care precisely, so we used as proxy variable the time from the beginning of symptoms and seeking medical attention. Nonetheless, in our study, we did not observe differences between We were unable to evaluate these factors in our analysis, but we consider this should be evaluated in further studies. Despite the large volume of research on the pandemic, studies aimed at analyzing the association between ethnicity and COVID-19 are limited 30 . According to our knowledge, this is the first study in Mexico that analyzes COVID-19 fatality risk in the indigenous population. Although the number of national indigenous population screened for SARS-CoV-2 is small (n = 8,835), it was possible to establish that they have higher COVID-19 fatality rates. These results, however, should be interpreted with caution as the nature of the data does not allow to fully understand the phenomenon occurred in the indigenous population with COVID-19, and because of the observed underrepresentation as well. Overall, our findings suggest that COVID-19 fatality is adversely affecting the indigenous population, particularly patients who received initial outpatient care. In addition, comorbidity Epidemiology Based on Current Evidence Centers for Disease Control and Prevention (CDC). Coronavirus disease 2019 Instituto Nacional de los Pueblos Indígenas -INPI. Indicadores Socioeconómicos de los Pueblos Indígenas de México United Nations. Indigenous Peoples at the United Nations Indigenous health part 1: determinants and disease patterns Critical review of social, environmental and health risk factors in the Mexican indigenous population and their capacity to respond to the COVID-19 Mortalidad por COVID-19 en México Risk factors for predicting mortality in elderly patients with COVID-19: A review of clinical data in China Predicting mortality due to SARS-CoV-2: A mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico Omar Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan Boletín sobre COVID-19: Letalidad por COVID-19 en la población indígena de México Información referente a casos COVID-19 en México Información sobre COVID-19. Instituto Nacional de Salud Pública Survival Analysis An Introduction to Survival Analysis Using Stata Ethnic and regional variations in hospital mortality from COVID-19 in Brazil: a cross-sectional observational study Improved measurement of racial/ethnic disparities in COVID-19 mortality in the United States Coronavirus (COVID-19) related deaths by ethnic group, England and Wales. The Office for National Statistics (ONS) Characteristics and clinical outcomes of adult patients hospitalized with Covid Nothing to disclose.Ethical approval: No ethical approval was required as all the data analyzed were publicly available.